Published Date : Apr 21, 2016
Diabetics and its rising prevalence in the globe is one of the most pressing concerns ahead of the global healthcare industry in the current scenario. The World health Organization (WHO) has revealed that diabetes affected near to 9% of the world’s young population aged 18 in 2014. By 2030, the disease is projected to become the seventh leading cause of mortality, coming in line with deadly diseases such as a variety of cardiovascular conditions, obesity, and a variety of cancers. In 2012, an estimated 1.5 mn people across the globe died directly owing to complications developed from diabetes.
The worrying rise in prevalence of the disease has boosted the global demand for insulin. Insulin is the hormone created in a normal person’s body by the pancreas, allowing the body to utilize the sugar consumed by a person in any form (like in the form of carbohydrates in the food, the excessive natural sugars in certain fruits, or in the direct form as glucose), and convert it into energy or to store glucose for use in the near future.
In diabetes, the pancreas does not create enough insulin to process the glucose in the body or the body cells are resistant to the effects of insulin. As a result, people with diabetes require additional dosages of insulin to maintain blood sugar levels.
In the present day scenario, the global insulin market is being heavily driven by the rising prevalence of diabetes across the globe and one of the most prominent drivers of the market is China. According to the International Diabetes Foundation, China is facing the world’s largest diabetes epidemic and the continuously rising rate of the disease in the country has surpassed that of the U.S. in terms of its occurrence.
A 2013 article in the JAMA (Journal of American Medical Association) publication stated that 11.60% of adults in China had been diagnosed with diabetes. This means that in 2013, China had about 114 mn adults with diabetes, which makes up for a third of the entire world’s diabetic population. This staggering pool of diabetics in China has come ahead as a major driver for the global insulin market in recent years and is also expected to drive the market over the next few years.